Coronavirus disease 19 (Covid-19) is a pandemic that affects every human on Earth. Mortality rates are greater in people with both cancer and Covid-19. In comparison, patients with non-Muscle-Invasive Bladder Cancer (NMIBC) had reduced susceptibility to moderate Covid-19 mortality. The treatment and clinical management of NMIBC are consistent with BCG-mediated intravesical adjuvant therapy as a protective function against tumors. BCG vaccination exhibits a non-specific protective role against respiratory infections. This non-specific effect of BCG is partially mediated by innate immune memory due to epigenetic changes in innate and adaptive immune system cells induced by the microbe. This editorial suggests that regularly test repurposed drugs include anti-cancer drugs till the proper antiviral drugs or vaccines will be developed.
Associated pathogenesis of bladder cancer and SARS-CoV-2 infection: a treatment strategy